Business Context and Reporting Period
This Form 8-K Current Report was filed by Elicio Therapeutics, Inc. on December 22, 2023. The filing discloses the entry into a material definitive agreement and the unregistered sale of equity securities on the same date.
Key Financial Metrics
- Transaction Type: Private placement of common stock.
- Shares Issued: 1,213,000 shares of Common Stock.
- Purchase Price: $5.81 per share.
- Gross Proceeds: Approximately $7.0 million.
- Purchaser: GKCC, LLC, an entity controlled by a director of the Company.
- Use of Proceeds: Advancement of the development pipeline, working capital, and general corporate purposes.
Note: This filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, or debt levels for the reporting period.
Material Changes
The primary material change is the increase in equity capital through the issuance of 1,213,000 shares to a related party. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
- Registration Obligation: The Company must file a registration statement with the SEC by March 31, 2024, to register the shares for resale by the Purchaser.
- Effectiveness Timeline: The Company must use commercially reasonable efforts to have the registration statement declared effective within 30 days of filing, or within 90 days of receiving written comments from the SEC.
- Penalties: The Subscription Agreement includes customary cash penalties for the Company's failure to meet specified filing and effectiveness time periods.
- Regulatory Status: The shares were sold without registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. They are restricted securities and cannot be resold in the U.S. without an effective registration statement or exemption.
Investor Verification Checklist
- Verify the closing of the Offering and receipt of the $7.0 million gross proceeds.
- Confirm the filing of the resale registration statement by the March 31, 2024 deadline.
- Review the Company's periodic reports (10-K/10-Q) for current cash position and burn rate to assess the impact of the new capital on runway.
- Monitor for any cash penalties incurred if the registration statement is not declared effective within the agreed timelines.